5:51 PM
 | 
Mar 18, 2008
 |  BC Extra  |  Clinical News

Tavocept misses Phase III endpoints

BioNumerik (San Antonio, Texas) said IV Tavocept ( BNP7787) did not meet the primary endpoint of preventing and reducing the severity of sporadic and cumulative...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >